CD8A and cancer: RAS‐driven cancers frequently express ligands called immune checkpoint molecules on their surface that bind their cognate receptors on immune cells of the TME including CD4 helper T‐cells and CD8 cytotoxic T‐cells, as well as natural killer cells resulting in their functional exhaustion and decreased ability to kill cancer cells.